DOCSLIB.ORG

A Matter of Record (301) 890-4188 FOOD and DRUG

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Matter of Record (301) 890-4188 FOOD and DRUG 1 1 FOOD AND DRUG ADMINISTRATION 2 CENTER FOR DRUG EVALUATION AND RESEARCH 3 4 5 6 PHARMACY COMPOUNDING ADVISORY COMMITTEE (PCAC) 7 8 9 Afternoon Session 10 11 12 13 Thursday, June 23, 2016 14 1:00 p.m. to 5:08 p.m. 15 16 17 18 FDA White Oak Campus 19 10903 New Hampshire Avenue 20 Building 31 Conference Center 21 The Great Room (Rm. 1503) 22 Silver Spring, Maryland A Matter of Record (301) 890-4188 2 1 Meeting Roster 2 DESIGNATED FEDERAL OFFICER (Non-Voting) 3 Cindy Hong, PharmD 4 Division of Advisory Committee and Consultant 5 Management 6 Office of Executive Programs, CDER, FDA 7 8 PHARMACY COMPOUNDING ADVISORY COMMITTEE MEMBERS 9 (Voting) 10 Michael A. Carome, MD, FASHP 11 (Consumer Representative) 12 Director of Health Research Group 13 Public Citizen 14 Washington, District of Columbia 15 16 Gigi S. Davidson, BSPh, DICVP 17 (U.S. Pharmacopeial Convention Representative) 18 Director of Clinical Pharmacy Services 19 North Carolina State University 20 College of Veterinary Medicine 21 Raleigh, North Carolina 22 A Matter of Record (301) 890-4188 3 1 John J. DiGiovanna, MD 2 Senior Research Physician 3 DNA Repair Section 4 Dermatology Branch 5 Center for Cancer Research 6 National Cancer Institute 7 Bethesda, Maryland 8 9 Padma Gulur, MD 10 Professor, Department of Anesthesiology and 11 Perioperative Care 12 University of California, Irvine 13 Orange, California 14 15 Stephen W. Hoag, PhD 16 Professor 17 Department of Pharmaceutical Science 18 University of Maryland, Baltimore 19 Baltimore, Maryland 20 21 22 A Matter of Record (301) 890-4188 4 1 William A. Humphrey, BSPharm, MBA, MS 2 Director of Pharmacy Operations 3 St. Jude’s Children’s Research Hospital 4 Memphis, Tennessee 5 6 Elizabeth Jungman, JD 7 Director, Public Health Programs 8 The Pew Charitable Trusts 9 Washington, District of Columbia 10 11 Katherine Pham, PharmD 12 Neonatal Intensive Care Unit Pharmacy Specialist 13 Children’s National Medical Center 14 Washington, District of Columbia 15 16 Allen J. Vaida, BSc, PharmD, FASHP 17 Executive Vice President 18 Institute for Safe Medication Practices 19 Horsham, Pennsylvania 20 21 22 A Matter of Record (301) 890-4188 5 1 Jurgen Venitz, MD, PhD 2 (Chairperson) 3 Associate Professor, Virginia Commonwealth 4 University 5 School of Pharmacy, Department of Pharmaceutics 6 Richmond, Virginia 7 8 PHARMACY COMPOUNDING ADVISORY COMMITTEE MEMBERS 9 (Voting) 10 Donna Wall, PharmD 11 (National Association of Boards of Pharmacy 12 Representative) 13 Clinical Pharmacist 14 Indiana University Hospital 15 Indianapolis, Indiana 16 17 18 19 20 21 22 A Matter of Record (301) 890-4188 6 1 PHARMACY COMPOUNDING DRUGS ADVISORY COMMITTEE 2 INDUSTRY REPRESENTATIVE MEMBERS (Non-Voting) 3 Ned S. Braunstein, MD 4 (Industry Representative) 5 Senior Vice President and Head of Regulatory 6 Affairs 7 Regeneron Pharmaceuticals, Inc. 8 Tarrytown, New York 9 10 William Mixon, RPh, MS, FIACP 11 (Industry Representative) 12 Former Owner 13 The Compounding Pharmacy 14 Hickory, North Carolina 15 16 17 18 19 20 21 22 A Matter of Record (301) 890-4188 7 1 TEMPORARY MEMBERS (Voting) 2 Jeffrey Brent, MD, PhD 3 (Participation in DMPS discussion) 4 Distinguished Clinical Professor of Medicine 5 University of Colorado School of Medicine and 6 Colorado School of Public Health 7 Denver, Colorado 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 A Matter of Record (301) 890-4188 8 1 C O N T E N T S 2 AGENDA ITEM PAGE 3 Expanded Access to Investigational 4 New Drugs 5 Jonathan Jarow, MD 10 6 Clarifying Questions from the Committee 23 7 503A Bulk Drug Substances List 8 FDA Presentations 9 Pyruvic Acid 10 Brenda Carr, MD 36 11 Clarifying Questions from the Committee 46 12 Open Public Hearing 50 13 Committee Discussion and Vote 84 14 503A Bulk Drug Substances List 15 FDA Presentations 16 Tea Tree Oil 17 Hon-Sum Ko, MD 90 18 Clarifying Questions from the Committee 104 19 Nominator Presentations – NCPA 20 Alexander Pytlarz, PharmD 116 21 Committee Discussion and Vote 128 22 A Matter of Record (301) 890-4188 9 1 C O N T E N T S (continued) 2 AGENDA ITEM PAGE 3 503A Bulk Drug Substances List 4 FDA Presentations 5 2,3-Dimercapto-1-propanesulfonic acid (DMPS) 6 Kathy Robie Suh, MD, PhD 140 7 Clarifying Questions from the Committee 148 8 Nominator Presentations - AANP 9 Paul Anderson, ND 157 10 Clarifying Questions from the Committee 165 11 Open Public Hearing 175 12 Committee Discussion and Vote 187 13 Adjournment 201 14 15 16 17 18 19 20 21 22 A Matter of Record (301) 890-4188 10 1 P R O C E E D I N G S 2 (1:00 p.m.) 3 DR. VENITZ: Let's reconvene our meeting, 4 please. Welcome to the afternoon session of the 5 PCAC. We're now going to take a little detour, 6 getting information on expanded access programs. 7 We'll have Dr. Jarow present on expanded access to 8 investigation of new drugs. 9 Dr. Jarow? 10 Presentation – Jonathan Jarow 11 DR. JAROW: Good afternoon, everyone. I'm 12 back, for those of you who were at the last 13 Compounding Advisory Committee meeting. 14 It was felt, after the last session and the 15 questions that came up, that it'd be worthwhile to 16 give an expanded-access IND-for-dummies talk to 17 answer a lot of the outstanding questions that 18 exist. 19 Although I wasn't here this morning, I was 20 at another meeting, I understand that a lot of 21 these issues came up again today. 22 So here's a summary of potential questions A Matter of Record (301) 890-4188 11 1 that people might ask about this process, and I'll 2 give you the short answers here. And then 3 hopefully, you have a copy of my slides because, at 4 the end, there's two slides with resources that you 5 go to for much more in-depth information. 6 But question number 1, is there a model for 7 expanded access to an unapproved drug or a formerly 8 compounded drug? And the answer is yes. 9 The best, the only existent model for 10 something like that right now is domperidone, which 11 recent had the protocol and materials posted online 12 for people to access, but that's in single-patient 13 INDs. 14 I don't think that's necessarily the best 15 model for all situations. And the one that I'm 16 going to put forward today is something called an 17 intermediate-sized access IND. So yes, there is a 18 model. 19 Can the sponsor charge patients for the 20 costs incurred, as well as the drug? And the 21 answer is yes. Can administrative costs be passed 22 on? The answer to that is yes. A Matter of Record (301) 890-4188 12 1 Who can serve as the sponsor of the IND? It 2 could be a manufacturer. It could be individual 3 physicians or other groups, and we'll get into some 4 details later on. 5 How is the drug dispensed? The sponsor 6 dispenses the drug directly or through an 7 investigator. 8 Are multiple courses of treatment possible? 9 The answer to this is also yes, provided applicable 10 requirements are met. This would be part of the 11 protocol. 12 I learned through practice talk internally 13 at FDA -- for those of you who have participated in 14 or run a multicenter clinical trial, this is simple 15 stuff, very routine and easy. 16 For those of you who never done this, it 17 probably seems very opaque and problematic. I'm 18 going to try and clarify this, but I'll also want 19 to say -- and it's going to come up again -- talk 20 to us. Talk to us. We are here to help. 21 So what are the eligibility criteria for an 22 expanded access protocol? One, the indication has A Matter of Record (301) 890-4188 13 1 to be a serious or immediately life-threatening 2 condition. There has to be no comparable or 3 satisfactory alternative therapy. 4 The potential patient benefit justifies the 5 potential risk, and the risks are not unreasonable 6 in the context of the disease or condition to be 7 treated, and it's providing the drug will not 8 interfere with ongoing clinical investigations that 9 could support marketing approval of the expanded 10 access use of that drug. 11 There are multiple types of expanded access. 12 Expanded access is basically access to an 13 unapproved drug, which we're going to call an 14 investigational drug, outside of the clinical trial 15 setting. 16 This is not for research, although 17 frequently the information gathered from expanded 18 access protocols may be used as part of an 19 application. But in general, the intention is, in 20 expanded access, to treat patients. 21 It could be submitted as a freestanding IND 22 or a protocol under an existing IND. They come in A Matter of Record (301) 890-4188 14 1 three flavors; single-patient, which would include 2 both emergency and non-emergency use, intermediate 3 size patient population, and a treatment protocol 4 or IND, which is for more widespread use. 5 For an intermediate-sized access IND, the 6 application must state whether the drug is being 7 developed for marketing.
Load more

Recommended publications
  • Evaluation of the Efficacy and Safety of Tavaborole Topical Solution, 5%, In
    Journal of Dermatological Treatment ISSN: 0954-6634 (Print) 1471-1753 (Online) Journal homepage: http://www.tandfonline.com/loi/ijdt20 Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies Aditya K. Gupta, Steve Hall, Lee T. Zane, Shari R. Lipner & Phoebe Rich To cite this article: Aditya K. Gupta, Steve Hall, Lee T. Zane, Shari R. Lipner & Phoebe Rich (2017): Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies, Journal of Dermatological Treatment, DOI: 10.1080/09546634.2017.1329510 To link to this article: http://dx.doi.org/10.1080/09546634.2017.1329510 Accepted author version posted online: 18 May 2017. Published online: 30 May 2017. Submit your article to this journal Article views: 41 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ijdt20 Download by: [Oregon Health & Science University Library] Date: 27 September 2017, At: 13:42 JOURNAL OF DERMATOLOGICAL TREATMENT, 2017 https://doi.org/10.1080/09546634.2017.1329510 ORIGINAL ARTICLE Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies Aditya K.
    [Show full text]
  • FDA Comments on CBD in Foods
    Popular Content Public Health Focus FDA and Marijuana: Questions and Answers 1. How is marijuana therapy being used by some members of the medical community? 2. Why hasn’t the FDA approved marijuana for medical uses? 3. Is marijuana safe for medical use? 4. How does FDA’s role differ from NIH and DEA’s role when it comes to the investigation of marijuana for medical use? 5. Does the FDA object to the clinical investigation of marijuana for medical use? 6. What kind of research is the FDA reviewing when it comes to the efficacy of marijuana? 7. How can patients get into expanded access program for marijuana for medical use? 8. Does the FDA have concerns about administering a cannabis product to children? 9. What is FDA’s reaction to states that are allowing marijuana to be sold for medical uses without the FDA’s approval? 10. What is the FDA’s position on state “Right to Try” bills? 11. Has the agency received any adverse event reports associated with marijuana for medical conditions? 12. Can products that contain cannabidiol be sold as dietary supplements? 13. Is it legal, in interstate commerce, to sell a food to which cannabidiol has been added? 14. In making the two previous determinations, why did FDA conclude that substantial clinical investigations have been authorized for and/or instituted about cannabidiol, and that the existence of such investigations has been made public? 15. Will FDA take enforcement action regarding cannabidiol products that are marketed as dietary supplements? What about foods to which cannabidiol has been added? 16.
    [Show full text]
  • HMSA ASO Topical Antifungals Jublia (Efinaconazole) Kerydin (Tavaborole
    PA Request Criteria HMSA ASO Topical Antifungals This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at 855-762-5207. Please contact CVS/Caremark at 855-240-0543 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Topical Antifungals. Patient Information Patient Name: Patient Phone: - - Patient ID: Patient Group No: Patient DOB: / / Prescribing Physician Physician Name: Physician - - Phone: Physician Fax: - - Physician Address: City, State, Zip: Drug Name (select from list of drugs shown) Jublia (efinaconazole) Kerydin (tavaborole) Oxiconazole Cream Oxistat Cream (oxiconazole) Quantity: ____________ Frequency: __________________ Strength: __________________ Route of Administration: _______________________ Expected Length of Therapy: _____________________ Diagnosis: ICD Code: __________________________________ Comments: _____________________________________________________ ______________________________________________________________________ ______________________________________________________________________ Please check the appropriate answer for each applicable question. 1. Is this a request for oxiconazole cream (Oxistat)? Y N 2. Is the requested drug being prescribed for any of the following: A) tinea corporis, B) tinea Y N cruris, C) tinea pedis, D) tinea versicolor? 3. Is the drug being prescribed for onychomycosis of the toenail(s) due to Trichophyton Y N rubrum and Trichophyton mentagrophytes? 4. Has the diagnosis been confirmed with a fungal diagnostic test (e.g., KOH preparation, Y N fungal culture, or nail biopsy)? I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.
    [Show full text]
  • Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Common Derm Conditions and Treatments
    4/10/17 Classes of Dermatologic Medications What is that?! Common Dermatologic Conditions and ● Topical Immune Suppressants ● Immune Suppressants How to Treat Them ● Vitamin D Derivatives ● Antibiotics, Antivirals, Antiparasitic Matthew Fox, MD ● Retinoids ● Antimalarials Assistant Professor, Division of Dermatology ● Biologic Agents Dell Medical School, University of Texas at Austin Director of Dermatologic Surgery, Seton Healthcare Family ● Chemotherapeutic agents Learning Objectives Approach to Dermatologic Conditions • Know the clinical subtypes of acne *Know the mechanism and recommended dosing of topical retinoids, oral antibiotics and oral retinoids in the management of acne Acne • Understand the clinical presentation cutaneous dermatophyte infection Infectious diseases of the Skin *Know the classes and recommended dosing of antifungal treatments • Recognize the clinical manifestations of dermatitis Eczema *Know the relative potencies, side effects and indications of topical steroids Psoriasis • Describe the classic clinical findings for psoriasis *Know the mechanism of action and side effects of systemic antipsoriatic medications Sun Damage / Actinic Keratoses • Know the pertinent history and physical exam findings associated with a diagnosis of skin cancer, including the ABCDEs of melanoma Fundamentals Words to the wise… • All medications have side effects If you advise the patients of side effects ahead of time, you are informing the • Always consider drug interactions, patient. including with food and supplements If you did not tell the patient about a known • Always consider pregnancy and lactation side effect until after they experience status that side effect, it is an excuse 1 4/10/17 Reference: Approach to Dermatologic Conditions • Wolverton SE, ed. Acne Comprehensive Infectious diseases of the Skin Dermatologic Drug Eczema nd Therapy, 2 Ed.
    [Show full text]
  • Vaccines, Diagnostics, and Treatments): Frequently Asked Questions
    Development and Regulation of Medical Countermeasures for COVID-19 (Vaccines, Diagnostics, and Treatments): Frequently Asked Questions June 25, 2020 Congressional Research Service https://crsreports.congress.gov R46427 SUMMARY R46427 Development and Regulation of Medical June 25, 2020 Countermeasures for COVID-19 (Vaccines, Agata Dabrowska Diagnostics, and Treatments): Frequently Analyst in Health Policy Asked Questions Frank Gottron Specialist in Science and In recent months, the Coronavirus Disease 2019 (COVID-19) pandemic has spread globally, with Technology Policy the United States now reporting the highest number of cases of any country in the world. Currently, there are few treatment options available to lessen the health impact of the disease and no vaccines or other prophylactic treatments to curb the spread of the virus. Amanda K. Sarata Specialist in Health Policy The biomedical community has been working to develop new therapies or vaccines, and to repurpose already approved therapeutics, that could prevent COVID-19 infections or lessen Kavya Sekar severe outcomes in patients. In addition, efforts have been underway to develop new diagnostic Analyst in Health Policy tools (i.e., testing) to help better identify and isolate positive cases, thereby reducing the spread of the disease. To this end, Congress has appropriated funds for research and development into new medical countermeasures (MCMs) in several recent supplemental appropriations acts. MCMs are medical products that may be used to treat, prevent, or diagnose conditions associated with emerging infectious diseases or chemical, biological, radiological, or nuclear (CBRN) agents. MCMs include biologics (e.g., vaccines, monoclonal antibodies), drugs (e.g., antimicrobials, antivirals), and medical devices (e.g., diagnostic tests).
    [Show full text]
  • Therapeutic Class Overview Antifungals, Topical
    Therapeutic Class Overview Antifungals, Topical INTRODUCTION The topical antifungals are available in multiple dosage forms and are indicated for a number of fungal infections and related conditions. In general, these agents are Food and Drug Administration (FDA)-approved for the treatment of cutaneous candidiasis, onychomycosis, seborrheic dermatitis, tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (Clinical Pharmacology 2018). The antifungals may be further classified into the following categories based upon their chemical structures: allylamines (naftifine, terbinafine [only available over the counter (OTC)]), azoles (clotrimazole, econazole, efinaconazole, ketoconazole, luliconazole, miconazole, oxiconazole, sertaconazole, sulconazole), benzylamines (butenafine), hydroxypyridones (ciclopirox), oxaborole (tavaborole), polyenes (nystatin), thiocarbamates (tolnaftate [no FDA-approved formulations]), and miscellaneous (undecylenic acid [no FDA-approved formulations]) (Micromedex 2018). The topical antifungals are available as single entity and/or combination products. Two combination products, nystatin/triamcinolone and Lotrisone (clotrimazole/betamethasone), contain an antifungal and a corticosteroid preparation. The corticosteroid helps to decrease inflammation and indirectly hasten healing time. The other combination product, Vusion (miconazole/zinc oxide/white petrolatum), contains an antifungal and zinc oxide. Zinc oxide acts as a skin protectant and mild astringent with weak antiseptic properties and helps to
    [Show full text]
  • Federal Register/Vol. 83, No. 31/Wednesday, February 14, 2018
    Federal Register / Vol. 83, No. 31 / Wednesday, February 14, 2018 / Notices 6563 Wireless Telecommunications Bureau Signed: DEPARTMENT OF HEALTH AND and Wireline Competition Bureau (the Dayna C. Brown, HUMAN SERVICES Bureaus) may implement, and (3) certify Secretary and Clerk of the Commission. Centers for Disease Control and its challenge. The USAC system will [FR Doc. 2018–03166 Filed 2–12–18; 4:15 pm] validate a challenger’s evidence using Prevention BILLING CODE 6715–01–P an automated challenge validation [CDC–2018–0004; NIOSH–233–B] process. Once all valid challenges have been identified, a challenged party that NIOSH List of Antineoplastic and Other chooses to respond to any valid FEDERAL RESERVE SYSTEM Hazardous Drugs in Healthcare challenge(s) may submit additional data Settings: Proposed Additions to the via the online USAC portal during the Change in Bank Control Notices; NIOSH Hazardous Drug List 2018 established response window. A Acquisitions of Shares of a Bank or AGENCY: Centers for Disease Control and challenged party may submit technical Bank Holding Company information that is probative regarding Prevention, HHS. ACTION: Notice of draft document the validity of a challenger’s speed tests, The notificants listed below have available for public comment. including speed test data and other applied under the Change in Bank device-specific data collected from Control Act (12 U.S.C. 1817(j)) and transmitter monitoring software or, SUMMARY: The National Institute for § 225.41 of the Board’s Regulation Y (12 alternatively, may submit its own speed Occupational Safety and Health test data that conforms to the same CFR 225.41) to acquire shares of a bank (NIOSH) of the Centers for Disease standards and requirements specified by or bank holding company.
    [Show full text]
  • Comparisons of Food and Drug Administration and European
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector VALUE IN HEALTH 15 (2012) 1108–1118 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval Health Policy Analyses Comparisons of Food and Drug Administration and European Medicines Agency Risk Management Implementation for Recent Pharmaceutical Approvals: Report of the International Society for Pharmacoeconomics and Outcomes Research Risk Benefit Management Working Group Yvonne Lis, PhD1, Melissa H. Roberts, MS2, Shital Kamble, PhD3, Jeff J. Guo, PhD4, Dennis W. Raisch, PhD5,* 1PAREXEL International, Uxbridge, UK; 2Lovelace Clinic Foundation Research, Albuquerque, New Mexico, USA; 3Quintiles-Outcome, Rockville, MD, USA; 4College of Pharmacy, University of Cincinnati Medical Center, Cincinnati, OH, USA; 5College of Pharmacy, University of New Mexico, Albuquerque, NM, USA ABSTRACT Objective: 1) To compare the Food and Drug Administration’s (FDA’s) requirements not included in RMPs were patient medication guides Risk Evaluation and Mitigation Strategies (REMS) and European (100% of the drugs), provider communication plans (38%), and routine Medicines Agency’s (EMA’s) Risk Management Plan (RMP) guidances monitoring of REMS (66%). RMP requirements not included in REMS and 2) to compare REMS and RMPs for specific chemical entities and were specific adverse event reporting (45% of the drugs), prospective biological products. Methods: FDA, EMA, and pharmaceutical com- registry studies (34%), prospective epidemiology studies (24%), addi- pany Web sites were consulted for details pertaining to REMS and tional trial data (28%), and Summary of Product Characteristics RMPs. REMS requirements include medication guides, communication contraindications (76%). Conclusions: Both REMS and RMPs provide plans, elements to ensure safe use, implementation systems, and positive guidance for identification, monitoring, and minimization of specified assessment intervals.
    [Show full text]
  • Therapeutic Class Overview Onychomycosis Agents
    Therapeutic Class Overview Onychomycosis Agents Therapeutic Class • Overview/Summary: This review will focus on the antifungal agents Food and Drug Administration (FDA)-approved for the treatment of onychomycosis.1-9 Onychomycosis is a progressive infection of the nail bed which may extend into the matrix or plate, leading to destruction, deformity, thickening and discoloration. Of note, these agents are only indicated when specific types of fungus have caused the infection, and are listed in Table 1. Additionally, ciclopirox is only FDA-approved for mild to moderate onychomycosis without lunula involvement.1 The mechanisms by which these agents exhibit their antifungal effects are varied. For ciclopirox (Penlac®) the exact mechanism is unknown. It is believed to block fungal transmembrane transport, causing intracellular depletion of essential substrates and/or ions and to interfere with ribonucleic acid (RNA) and deoxyribonucleic acid (DNA).1 The azole antifungals, efinaconazole (Jublia®) and itraconazole tablets (Onmel®) and capsules (Sporanox®) works via inhibition of fungal lanosterol 14-alpha-demethylase, an enzyme necessary for the biosynthesis of ergosterol. By decreasing ergosterol concentrations, the fungal cell membrane permeability is increased, which results in leakage of cellular contents.2,5,6 Griseofulvin microsize (Grifulvin V®) and ultramicrosize (GRIS-PEG®) disrupts the mitotic spindle, arresting metaphase of cell division. Griseofulvin may also produce defective DNA that is unable to replicate. The ultramicrosize tablets are absorbed from the gastrointestinal tract at approximately one and one-half times that of microsize griseofulvin, which allows for a lower dose of griseofulvin to be administered.3,4 Tavaborole (Kerydin®), is an oxaborole antifungal that interferes with protein biosynthesis by inhibiting leucyl-transfer ribonucleic acid (tRNA) synthase (LeuRS), which prevents translation of tRNA by LeuRS.7 The final agent used for the treatment of onychomycosis, terbinafine hydrochloride (Lamisil®), is an allylamine antifungal.
    [Show full text]
  • New Drugs Are Not Enough‑Drug Repositioning in Oncology: an Update
    INTERNATIONAL JOURNAL OF ONCOLOGY 56: 651-684, 2020 New drugs are not enough‑drug repositioning in oncology: An update ROMINA GABRIELA ARMANDO, DIEGO LUIS MENGUAL GÓMEZ and DANIEL EDUARDO GOMEZ Laboratory of Molecular Oncology, Science and Technology Department, National University of Quilmes, Bernal B1876, Argentina Received August 15, 2019; Accepted December 16, 2019 DOI: 10.3892/ijo.2020.4966 Abstract. Drug repositioning refers to the concept of discov- 17. Lithium ering novel clinical benefits of drugs that are already known 18. Metformin for use treating other diseases. The advantages of this are that 19. Niclosamide several important drug characteristics are already established 20. Nitroxoline (including efficacy, pharmacokinetics, pharmacodynamics and 21. Nonsteroidal anti‑inflammatory drugs toxicity), making the process of research for a putative drug 22. Phosphodiesterase-5 inhibitors quicker and less costly. Drug repositioning in oncology has 23. Pimozide received extensive focus. The present review summarizes the 24. Propranolol most prominent examples of drug repositioning for the treat- 25. Riluzole ment of cancer, taking into consideration their primary use, 26. Statins proposed anticancer mechanisms and current development 27. Thalidomide status. 28. Valproic acid 29. Verapamil 30. Zidovudine Contents 31. Concluding remarks 1. Introduction 2. Artesunate 1. Introduction 3. Auranofin 4. Benzimidazole derivatives In previous decades, a considerable amount of work has been 5. Chloroquine conducted in search of novel oncological therapies; however, 6. Chlorpromazine cancer remains one of the leading causes of death globally. 7. Clomipramine The creation of novel drugs requires large volumes of capital, 8. Desmopressin alongside extensive experimentation and testing, comprising 9. Digoxin the pioneer identification of identifiable targets and corrobora- 10.
    [Show full text]
  • Drug Development and Clinical Trials 101
    DRUG DEVELOPMENT AND CLINICAL TRIALS 101 March 27, 2021 A Resource of PWSA | USA | pwsausa.org DISCOVERY - PHASE 1 Dean S. Carson, PhD, Saniona, Inc. A Resource of PWSA | USA | pwsausa.org DRUG DISCOVERY AND DEVELOPMENT Why is it important? • Rare hormone producing tumor of the anterior pituitary gland • Cabergoline, an ergot derivative, is a potent dopamine D2 receptor agonist that blocks pituitary production of prolactin • Ergot is a fungus that grows on rye and related plants, and produces alkaloids that can cause ergotism in humans and animals that eat the contaminated grain • Painful seizures, mania, psychosis, headaches, nausea, vomiting A Resource of PWSA | USA | pwsausa.org 3 PHARMACOLOGY • Pharmacology is the science of how • Clinical Pharmacology applies the basic drugs and biologics act on biological science and principles of pharmacology to systems and how the system responds to the practice of medicine the drug Basic science Translational pharmacology Clinical practice Doctors, pharmacists, dentists, veterinarians use the information discovered from pharmacology to select the best medications to treat patients A Resource of PWSA | USA | pwsausa.org 4 MECHANISM OF ACTION • Modern drug discovery is a mechanism • What are the known consequences of that driven field mechanism in a disease state? ie. • Nearly all new experimental therapeutics potential efficacy have a defined mechanism-of-action and • What are the known consequences of that most have companion diagnostics allowing mechanism in healthy systems? ie. researchers to
    [Show full text]